The Society of Nuclear Medicine’s campaign to guide advanced molecular imaging techniques into clinical practice has passed the halfway point in its goal of collecting $5 million to fund the effort.
The Society of Nuclear Medicine's campaign to guide advanced molecular imaging techniques into clinical practice has passed the halfway point in its goal of collecting $5 million to fund the effort.
The SNM announced in March that donors had pledged $3.3 million. The money will support a five-year action plan to move molecular imaging research from bench to bedside. The plan proposes strategies to nuture promising MI techniques as they progress from early laboratory development to adoption in medical practice.
To coordinate that effort, the SNM has hired Marybeth Howlett as director of its Molecular Imaging Center of Excellence. Howlett was the founding executive director of the Public Health Policy Advisory Board, a nonpartisan group created by former Secretary of Health and Human Services Louis W. Sullivan in Washington, DC.
The center has several development efforts pending:
The campaign's successful fund-raising efforts since June 2006 underscore the program's importance, according to SNM President Dr. Martin P. Sandler.
"We are pleased that innovative corporate leaders believe in SNM and support its mission," he said.
Molecular imaging represents a unique departure from traditional anatomic approaches to diagnosis with medical imaging. By operating at cellular and subcellular levels, MI promises to diagnose diseases at their earliest stages to allow effective treatment, sometimes before physical symptoms and physiological damage appear.
"Molecular imaging is at the forefront of personalized medicine, which eventually will allow us to tailor the treatment of a disease to each individual patient," Sandler said.
For more information from the Diagnostic Imaging archives:
Report from SNM: Society launches Bench to Bedside molecular imaging campaign
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.